{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"These analyses were conducted using available archival formalin-fixed, paraffin-embedded sections from surgical specimens. Each sample was tested to determine whether there was HER2 amplification.","groups":[{"description":"Patients receive afatinib dimaleate PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.\n\nafatinib dimaleate: Given PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Afatinib)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Analysis population included those in the main Phase II study. Two patients did not have a sample to analyze","reportingStatus":"POSTED","timeFrame":"Baseline","title":"HER2 Expression Status","type":"SECONDARY","unitOfMeasure":"Participants"}